(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR return of 15.1% since its launch. Ranked 40 in Sectoral category. Return for 2025 was -3.1% , 2024 was 42.9% and 2023 was 38.2% . NAV as on 4 Sep 26 ₹342.841 ↓ -1.33 (-0.39 %) Net Assets (AUM) as on 31 Jul 2026 ₹1,371 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 0.66 Expense Ratio 2.26 % Sharpe Ratio 0.511 Information Ratio 0.05 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 4 Sep 26 Duration Returns 1 Month 1.8% 3 Month 12.1% 6 Month 23.2% 1 Year 17.2% 3 Year 23.9% 5 Year 15% 10 Year 15 Year Since launch 15.1% Historical Annual Returns
Year Returns 2024 -3.1% 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% Growth of 10k Over Years
Date Value 31 Aug 21 ₹10,000 31 Aug 22 ₹8,732 31 Aug 23 ₹10,641 31 Aug 24 ₹16,559 31 Aug 25 ₹16,996 31 Aug 26 ₹20,298 Asset Allocation
Asset Class Value Cash 2.92% Equity 97.08% Sector Allocation
Sector Value Health Care 96.17% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 9% ₹119 Cr 600,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 6% ₹76 Cr 94,707
↑ 465 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331Drug Manufacturers - Specialty & Generic 5% ₹66 Cr 190,000
↓ -4,021 Caplin Point Laboratories Ltd (Healthcare)
Equity, Since 31 Dec 23 | CAPLIPOINTDrug Manufacturers - Specialty & Generic 4% ₹54 Cr 215,000
↑ 15,000 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 500257Drug Manufacturers - Specialty & Generic 4% ₹49 Cr 203,834 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - Specialty & Generic 4% ₹49 Cr 195,000
↓ -20,251 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 3% ₹47 Cr 53,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 3% ₹42 Cr 370,000
↑ 80,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEMDrug Manufacturers - Specialty & Generic 3% ₹42 Cr 73,830 Global Health Ltd (Healthcare)
Equity, Since 31 Oct 24 | MEDANTAMedical Care Facilities 3% ₹39 Cr 274,290
↑ 14,290
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 4.25 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹342.841
↓ -1.33 23.25 % 17.2 % 23.91 % 15.01 % UTI Healthcare Fund
Normal Dividend, Payout ₹264.968
↓ -1.03 23.25 % 17.2 % 23.91 % 15.01 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹264.968
↓ -1.03 23.25 % 17.2 % 23.91 % 15.01 % Data as on 4 Sep 26